June 12, 2025

Vegetarian Diet Linked to Lower Cancer Incidence

A large North American cohort study found that vegetarian diets were associated with lower risks of several site-specific cancers, including colorectal, stomach, breast, prostate, and lymphoproliferative cancers.

Conexiant

June 10, 2025

Heavy Drinking Ups Pancreatic Cancer Risk, Large Study Finds

Each 10-g increase in daily alcohol intake was linked to a 3% rise in risk.

Conexiant

June 09, 2025

Appendix Tumors Climb for Millennials, Gen Z

Younger generations—particularly individuals born after 1980—face higher rates of appendiceal cancer, with incidence increasing more than fourfold in recent decades, according to a new study.

Conexiant

June 06, 2025

Lower-Dose Treatment Effective in Anal Cancer Trial, Study

In a recent clinical trial, researchers found that a reduced-dose chemoradiotherapy regimen for early-stage anal cancer may be comparable to standard treatment in achieving short-term tumor response, while causing fewer serious side effects.

Conexiant

June 06, 2025

FDA Monthly Round-up: Key May Updates

May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.

Conexiant

June 04, 2025

Chemo Killed Her. A Test Might've Saved Her.

A fatal enzyme deficiency turned a common chemo drug toxic. With testing available—but rarely used—are clinicians missing a lifesaving step?

KFF Health News

June 03, 2025

FDA Grants Breakthrough Status to Shield Test

The methylation-based blood assay is designed for screening multiple cancer types.

Conexiant

June 02, 2025

Exercise After Chemotherapy Improves Colorectal Cancer Survival

A long-term clinical trial found that structured exercise after colon cancer treatment improved survival outcomes and reduced recurrence rates, offering evidence to support physical activity as part of survivorship care.

Conexiant

May 30, 2025

Extra Boost Before Surgery Shows Promise

Tevimbra added to chemo before esophageal cancer surgery doubled complete response rates in a phase 2 trial, hinting at a future shift in standard care.

Reuters